Drugs / TP-102
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04803708 | Mar 2021 → Aug 2022 | Acinetobacter infectious disease, Pseudomonas aeruginosa infectious disease, staphylococcus aureus infection, ulcer of lower limbs | Technophage, SA | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05948592 | Nov 2023 → Oct 2025 | — | Technophage, SA | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2025-01-03 | Technophage, SA | Results TP-102 Phase I/IIa clinical trial results published in Med by Cell Press technophage.pt ↗
Our Phase I/IIa study results for TP-102, an innovative bacteriophage cocktail targeting infected diabetic foot ulcers, demonstrated promising outcomes and are depicted in the paper entitled “ Randomized double-blind study on safety and tolerability of TP-102 phage cocktail in patients with infected and non-infected diabetic foot ulcers “. |
| 2023-05-10 | Technophage, SA | Results TP-102 clinical trial presented at ECCMID 2023 technophage.pt ↗
Overall, no treatment related adverse events associated to TP-102 or placebo were reported during the trial in both cohorts. |
| 2023-05-05 | Technophage, SA | Results TP-102 compassionate uses cases presented at ECCMID 2023 technophage.pt ↗
Technophage is proud to share that local application of TP-102 together with standard of care lead to an improved outcome of these complicated diabetic foot infections and complete resolution after long-term follow-up. |
| 2022-12-16 | Technophage, SA | Results TechnoPhage announces completion of innovative clinical trial with bacteriophage cocktail indicated for the treatment of diabetic foot infections technophage.pt ↗
Overall, the safety data obtained in this study showed that the biologic was well tolerated by patients, exhibiting a favorable safety profile, with no adverse effects related to the application of the product. |
| 2022-12-12 | Technophage, SA | Results TechnoPhage Announces Application of TP-102 Product in Two Compassionate Use Cases technophage.pt ↗
“both patients improved dramatically”, and adding that in the present “they are fine and continue to be followed up in an outpatient clinic”. |
| 2021-11-04 | Technophage, SA | Results TechnoPhage Announces First Clinical Safety Results with Innovative Biological Product TP-102 technophage.pt ↗
According to the data obtained from the patients included in this first part of the study, which was analyzed by the Safety Committee, there were no adverse effects associated with the study product. |
| 2021-05-14 | Technophage, SA | Regulatory Technophage announces FDA Fast Track Designation Granted to TP-102 for the treatment of patients with infected diabetic foot ulcers caused by Pseudomonas aeruginosa, Staphylococcus aureus and/or Acinetobacter baumannii technophage.pt ↗
Technophage announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TP-102, the company’s first bacteriophage cocktail, for the treatment of infected diabetic foot ulcers caused by three different bacteria ( Pseudomonas aeruginosa, Staphylococcus aureus and/or Acinetobacter baumannii ). |
| 2020-10-06 | Technophage, SA | Regulatory TechnoPhage announces U.S. FDA clearance of IND application to initiate clinical trial technophage.pt ↗
U.S. FDA has just cleared the IND application of bacteriophage cocktail TP-102 to initiate Phase I/IIa clinical trial. |
| 2014-07-31 | Technophage, SA | Regulatory TechnoPhage receives FDA clearance to begin human clinical trials of an innovative biological therapeutic technophage.pt ↗
TECHNOPHAGE, a biotechnology company headquartered in Lisbon, Portugal, announced today that the company has received authorization from U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for TP-102, a bacteriophage cocktail for the treatment of infected chronic ulcers, namely diabetic foot infections. |
All press releases naming this drug 17 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TP-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05948592 ↗ |
| Modality | Other / unclassified | “TP-102 bacteriophage cocktail” PMID 39740667 ↗ Dec 2024 |
| Route | Topical | “applied topically” NCT04803708 ↗ |